Impact of a VI-polysaccharide conjugate vaccine in preventing Typhoid Fever in an endemic setting, Lalitpur, Nepal
<p>Globally, an estimated 11 to 21 million cases of febrile illness and 117,000 to 161,000 deaths are attributed to typhoid fever each year. Typhoid fever is prevalent mainly in low-resource settings with poor water, and inadequate sanitation and hygiene facilities, with South Asia accounting...
Auteur principal: | Shakya, M |
---|---|
Autres auteurs: | Pollard, A |
Format: | Thèse |
Langue: | English |
Publié: |
2022
|
Sujets: |
Documents similaires
-
Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study
par: Maile T. Phillips, et autres
Publié: (2023-03-01) -
Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial
par: Sodiomon B. Sirima, et autres
Publié: (2021-07-01) -
Costs of typhoid vaccination for international travelers from the United States
par: Heesoo Joo, et autres
Publié: (2025-03-01) -
Single and two-dose typhoid conjugate vaccine safety and immunogenicity in HIV-exposed uninfected and HIV-unexposed uninfected Malawian children
par: Nginache Nampota-Nkomba, et autres
Publié: (2024-12-01) -
Global diversity and antimicrobial resistance of typhoid fever pathogens: Insights from a meta-analysis of 13,000 Salmonella Typhi genomes
par: Megan E Carey, et autres
Publié: (2023-09-01)